Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer
Reason given: Recruitment lower than expected. The proportion of patients with mGSTPi undetectable prior to chemo. was significantly higher than anticipated. Decision made to close due to insufficient patient numbers to able to obtain meaningful data collection.
Key facts
- Where
- Albury, Camperdown, Darlinghurst, Dubbo, Frankston, Shepparton, Sydney, and Traralgon, AustraliaSee the 8 sites
- Phase
- Phase 2
Where in Australia
- Border Medical Oncology Research Unit / The Border Cancer HospitalAlbury, AustraliaNo longer taking part
- Chris O'Brien LifehouseCamperdown, AustraliaNo longer taking part
- St Vincent's HospitalDarlinghurst, AustraliaNo longer taking part
- Dubbo Base HospitalDubbo, AustraliaNo longer taking part
- Frankston Hospital-Peninsula HealthFrankston, AustraliaNo longer taking part
- Goulburn Valley HealthShepparton, AustraliaNo longer taking part
- Concord Repatriation General HospitalSydney, AustraliaNo longer taking part
- Latrobe Regional HospitalTraralgon, AustraliaNo longer taking part
Trial details
- Who runs it
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Trial code
- NCT04918810
- Record updated
- 22 November 2024
- Original description
The purpose of this study is to see if a prostate cancer marker in the blood (mGSTP1) can be used to guide chemotherapy treatment. Based on the level of this blood marker, some people may be able to have breaks in treatment rather than having chemotherapy continuously which is the current standard of care. This study will tell us if having these treatment breaks guided by mGSTP1 can improve how people feel during treatment while still treating the prostate cancer effectively.Read full original descriptionShow less
A Phase II Trial of Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to see if a prostate cancer marker in the blood (mGSTP1) can be used to guide chemotherapy treatment. Based on the level of this blood marker, some people may be able to have breaks in treatment rather than having chemotherapy continuously which is the current standard of care. This study will tell us if having these treatment breaks guided by mGSTP1 can improve how people feel during treatment while still treating the prostate cancer effectively.
Docetaxel is a chemotherapy drug that is approved to treat prostate cancer and has been used for many years to treat prostate cancer like yours. Your doctor has already discussed this with you and you have both agreed that docetaxel is the best treatment for you to have at this time. You will have already started this chemotherapeutic treatment with docetaxel.
PRESCREENING INCLUSION CRITERIA; Patient has provided written informed consent using the GUIDE pre-screening PICF; Age ≥ 18 years at the time of pre-screening consent; Males with metastatic castration-resistant prostate cancer (as per PCWG3) AND are planned to commence docetaxel chemotherapy; WHO Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Appendix 1); Histological confirmation of prostate cancer; Patients must have adequate bone marrow and hepatic function within 14 days prior Cycle 1 day 1:; Haemoglobin ≥ 90 g/L independent of transfusions (no red blood cell transfusion in last 4 weeks); Platelets ≥ 100 x 109/L; Absolute neutrophil count (ANC) ≥ 1.5 x 109/L; Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN); Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) ≤ 2.5 x ULN; Willing and able to comply with all pre-screening study requirements, including blood tests for mGSTP1 analysis before and during docetaxel treatment; PRESCREENING EXCLUSION CRITERIA; Prior docetaxel or cabazitaxel chemotherapy for castration-resistant prostate cancer; Prior docetaxel in the castration sensitive prostate cancer setting within the previous 2 years; Known hypersensitivity to docetaxel or its excipients; Concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety; Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol; MAIN SCREENING INCLUSION CRITERIA; Patient has provided written informed consent for the main GUIDE study PICF; Patient has a detectable plasma mGSTP1 deoxyribonucleic acid (DNA) as measured by central laboratory at prescreening prior to commencing first cycle of docetaxel chemotherapy; Patient has commenced 3 cycles of docetaxel; Patient has undetectable plasma mGSTP1 DNA as measured by central laboratory from blood taken prior to the third cycle of docetaxel; Patient is willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments; MAIN SCREENING EXCCLUSION CRITERIA; Known hypersensitivity to docetaxel or its excipients; Concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety; Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol; Progressive disease by RECIST 1.1 within the first 3 cycles of docetaxel.